ethidium bromide has been researched along with zithromax in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bradbury, BJ; Buechter, DD; Cheng, J; Deshpande, M; Mushtaq, G; Podos, SD; Pucci, MJ; Thanassi, JA; Thoma, CL; Vigliotti, GA | 1 |
Kamal, N; Shafer, WM | 1 |
Barreca, ML; Cannalire, R; Cecchetti, V; Couto, I; Felicetti, T; Machado, D; Manfroni, G; Massari, S; Sabatini, S; Santos Costa, S; Tabarrini, O; Viveiros, M | 1 |
3 other study(ies) available for ethidium bromide and zithromax
Article | Year |
---|---|
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
Topics: Animals; Anti-Infective Agents; Drug Resistance, Bacterial; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Mice; Microbial Sensitivity Tests; Quinolones; Thiazoles | 2007 |
Biologic activities of the TolC-like protein of Neisseria meningitidis as assessed by functional complementation in Escherichia coli.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Escherichia coli; Escherichia coli Proteins; Genetic Complementation Test; Hemolysin Proteins; Humans; Microbial Sensitivity Tests; Neisseria meningitidis | 2010 |
Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
Topics: Anti-Bacterial Agents; Drug Design; Genistein; Mycobacterium avium; Quinolones | 2017 |